Lacks opposing viewpoints: Stability at head of FDA good for biotech

Biased Journalism Category: ARTICLES THAT LACK VETTING OF SOURCES AND/OR OPPOSING VIEWPOINTS
Media item: Stability at head of FDA good for biotech
Publisheed by: Washington Business Journal
Author: Bill Flook, Staff Reporter

On Nov. 8th, 2012 the following letter was sent to Bill Flook, followed by a second request on Nov. 16th, 2012. No response, so we are posting our comments here, and invite a reply from Mr. Flook.

Dear Mr. Flook,

Our group, Patients For Stem Cells, represents patients who have been denied access to our own stem cells because the FDA has regulated our cells as drugs. We oppose this decision and believe it is a violation of our basic rights. Your article, “Stability of FDA good for biotech, say GlycoMimetics CEO”, fails to acknowledge the vested interest that Rachel King, BIO and others have in maintaining the relationship they have established with FDA Commissioner, Margaret Hamburg. In the interests of good journalism, we know that you will undoubtedly be in favor of presenting opposing viewpoints and vetting those that you use as sources in your article. We would like a chance for a few of us to speak with you or correspond with you. Thank you in advance for the opportunity.

Regards,
Patients For Stem Cells

0 comments